ONXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Onyx Pharmaceuticals, Inc.'s research and development for the three months ended in Jun. 2013 was $102.8 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2013 was $362.3 Mil.
This is the expense the company spent on research and development.
Onyx Pharmaceuticals, Inc. Research & Development for the trailing twelve months (TTM) ended in Jun. 2013 was 85.667 (Sep. 2012 ) + 82.573 (Dec. 2012 ) + 91.302 (Mar. 2013 ) + 102.761 (Jun. 2013 ) = $362.3 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Onyx Pharmaceuticals, Inc. Annual Data
|Research & Development||33.6||35.8||63.1||31.0||83.3||123.7||128.5||185.7||268.1||325.3|
Onyx Pharmaceuticals, Inc. Quarterly Data
|Research & Development||62.5||63.0||58.5||84.0||80.7||76.4||85.7||82.6||91.3||102.8|